McCrimmon RJ, Al Sifri S, Emral R, Mohan V, et al. Advancing therapy with iGlarLixi versus Premix 70/30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomised controlled trial. Diabetes Obes Metab 2021 Feb 19. doi: 10.1111/dom.14354.
PMID: 33606908